Bio Plus Co

Bio Plus Co FCF Yield

The Free Cash Flow Yield of Bio Plus Co (099430.KQ) as of Nov 20, 2026 is -10.06 %. In the previous year, Free Cash Flow Yield was -22.53 % — a change of -55.36% (higher).

FCF Yield

-10.06 %

YoY

-55.36%

Last updated:

Free Cash Flow Yield of Bio Plus Co is 2025 -10.06 % . Free Cash Flow Yield of Bio Plus Co was 2024 -22.53 % . It decreases by -55.36% higher compared to the previous year.

The Bio Plus Co FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
0.73 KRW
Jan 1, 2019
-0.47 KRW
Jan 1, 2020
2.71 KRW
Jan 1, 2021
-0.61 KRW
Jan 1, 2022
2.02 KRW
Jan 1, 2023
-1.68 KRW
Jan 1, 2024
-22.53 KRW
Jan 1, 2025
-10.06 KRW
The Bio Plus Co FCF Yield history
YEARFCF YieldYoY
-10.06 %-55.36%
-22.53 %+1,244.21%
-1.68 %-182.99%
2.02 %-432.38%
-0.61 %-122.41%
2.71 %-676.84%
-0.47 %-164.28%
0.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

Free Cash Flow Yield of Bio Plus Co is -10.06 % in 2025.

Free Cash Flow Yield of Bio Plus Co changed from -22.53 % to -10.06 %, representing a -55.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Bio Plus Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Bio Plus Co

All Key Metrics — Bio Plus Co